Skip Navigation


Journal of Tropical Pediatrics Advance Access originally published online on October 1, 2008
Journal of Tropical Pediatrics 2009 55(3):155-159; doi:10.1093/tropej/fmn080
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/3/155    most recent
fmn080v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in J Trop Pediatr
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kumarasamy, N.
Right arrow Articles by Solomon, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kumarasamy, N.
Right arrow Articles by Solomon, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India

N. Kumarasamya, Kartik K. Venkateshb,c, Bella Devaleenola, S. Poongulalia, S. N. Mothid and Suniti Solomona

aYRG Centre for AIDS Research and Education, VHS, Chennai 600113, Tamil Nadu, India
bMiriam Hospital
cBrown University Medical School, Providence, RI, USA
dAsha Kirana Foundation, Mysore, Karnataka, India

Correspondence: Dr N. Kumarasamy; Chief Medical Officer, YRG Centre for AIDS Research and Education, VHS, Taramani, Chennai 600113, India. E-mail <kumarasamy{at}yrgcare.org>.


  Abstract

HIV-infected children in resource-limited settings are increasingly gaining greater access to highly active antiretroviral therapy (HAART) but documented longitudinal data remains limited. We aimed to study the clinical and immunological outcomes among 67 South Indian HIV-infected children with >18 months of follow-up on HAART at a tertiary HIV care program. The median CD4 cell count at enrolment was 290 cells µl–1 and at treatment initiation was 225 cells µl–1. Patients demonstrated a significant rise in their CD4 cell counts between treatment initiation and after 6 months (701 cells µl–1; p = 0.007), 12 months (741 cells µl–1; p = 0.037), and 18 months of therapy (718 cells µl–1; p = 0.005). The most common adverse events to therapy were nausea (20.9%) and rash (25.4%). Over one-fifth of patients (25.4%) substituted therapy due to toxicities and 19.4% of patients switched to second-line protease inhibitor-containing regimens. In this South Indian pediatric cohort, generic HAART was safe, effective and relatively well tolerated.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in J Trop Pediatr:

In this Issue June 2009

J Trop Pediatr 2009 55: i. [FREE Full Text]  





Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.